The EBOVAC2 project is one of 8 projects funded under IMI Ebola+ programme that was launched in response to the Ebola virus disease outbreak. The project aims to assess the safety and efficacy of a novel prime boost preventive vaccine regimen against Ebola Virus Disease (EVD).

To expedite the development of the vaccine regimen, Phase 2 trials and a Phase 2B study will be carried out in parallel and therefore coordinated by two separate teams within EBOVAC1 (Phase 1 and Phase 2B large scale safety and immunogenicity study) and EBOVAC2 (Phase 2 trial) projects.

lab                                           © Janssen

Between them, the EBOVAC projects will assess, through phase I and phase 2 trials in Europe and Africa, as well as a Phase 2B large scale safety and immunogenicity study, the safety and tolerability of the vaccine regimen in response to the urgent public health need raised by the Ebola epidemic.

Read more


  • 22 April 2016

    EBOVAC1 has published their first report on Phase 1 data in the April 19th 2016 issue of JAMA.             Press release and more information                                  ...

  • 04 April 2016

    The first subject was vaccinated on 30 March 2016 at the University of Nairobi, Kenya

  • 29 March 2016

    The 1st EBOVAC2 Newsletter is available!

  • 29 February 2016

    The first subject was randomized on 10 December 2016 at Makerere University in Uganda.

  • 29 February 2016

    The first subject was randomized at CHU Treichville in Côte d'Ivoire on 26 February 2016.

  • 11 February 2016

    The first subject was randomized at the Centre Muraz, Burkina Faso on the 11th of February 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research

ebovac2 in numbers

ebovac2 in numbers

    4 institutes, 1 Industrial partner,1 private company
    in charge of Management


    states involved


    €22,790,820 (IMI JU funding);
    EFPIA contribution: €15.1 million


    1st December 2014 – 30 November 2017

ebovac1 trials

  • Phase 1

    Trial countries: UK and selected African countries

  • Large-scale efficacy study or expanded safety and immunogenicity study in Sierra Leone

    More information on ebovac1 trials coming soon

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA